- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01776684
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
January 25, 2013 updated by: Myung-Ju Ahn, Samsung Medical Center
Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
Contact:
- Myung-Ju Ahn, M.D., Ph.D.
- Email: silkahn@skku.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1. Histologically confirmed NSCLC 2. Aged of or older than 20 years 3. ECOG performance status 0-2 4. Adequate hematological, renal, hepatic function 5. Patients with tumors harboring EGFR mutation (del 19 or L858R mutation) 6. Patient who are about to be treated with EGFR TKI (gefitinib, erlotinib or other EGFR TKI) 7. At least more than one measurable disease 8. Informed consent
Exclusion Criteria:
- 1. Active infection 2. Active bleeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EGFR positive arm
Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
detection of resistant gene
Time Frame: 24 months
|
To evaluate the efficiency of castPCR method for detection of resistance genes, especially, T790M mutation from serially collected plasma DNA in non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2012
Primary Completion (Anticipated)
May 1, 2014
Study Completion (Anticipated)
May 1, 2015
Study Registration Dates
First Submitted
January 23, 2013
First Submitted That Met QC Criteria
January 25, 2013
First Posted (Estimate)
January 28, 2013
Study Record Updates
Last Update Posted (Estimate)
January 28, 2013
Last Update Submitted That Met QC Criteria
January 25, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Gefitinib
- Afatinib
Other Study ID Numbers
- 2011-10-054
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on EGFR Mutation Positive Non-small Cell Lung Cancer
-
Centro de Tratamiento e Investigación sobre Cáncer...Not yet recruitingNon Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 MutationColombia
-
Blueprint Medicines CorporationTerminatedNeoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditionsUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingNon-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle DeregulationChina
-
GenoSaberSun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...UnknownNon Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
-
China Medical University HospitalNot yet recruitingNon-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
-
Sun Yat-sen UniversityRecruitingNon-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline MutationsChina
-
AstraZenecaTerminated
-
SciClone PharmaceuticalsUnknownEGFR Mutation Positive Non Small Cell Lung CancerItaly
-
European Organisation for Research and Treatment...Active, not recruitingEGFR Mutation Positive Non Small Cell Lung CancerUnited Kingdom
-
Hellenic Cooperative Oncology GroupCompletedNon Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Gene Mutation
Clinical Trials on EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
-
China Medical University, ChinaGeneral Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaboratorsUnknownNon Small Cell Lung Cancer
-
Tian XieLinkDoc Technology (Beijing) Co. Ltd.RecruitingAdenocarcinoma | Carcinoma | Non-Small-Cell Lung CancerChina
-
Peking University Third HospitalUnknownNonsmall Cell Lung CancerChina
-
China Medical University HospitalNot yet recruitingNon-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
-
Boehringer IngelheimCompletedNon-squamous, Non-Small Cell Lung CancerUnited Kingdom
-
Zhejiang Cancer HospitalUnknownNon-small Cell Lung CancerChina
-
Peking UniversityHangzhou DIAN Medical Diagnostic Center Co., Ltd., ChinaRecruitingGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive CancerChina
-
First People's Hospital of HangzhouUnknownLung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
-
Instituto Nacional de Cancerologia de MexicoUnknownEGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell AdenocarcinomaMexico
-
Sichuan Cancer Hospital and Research InstituteJiangsu HengRui Medicine Co., Ltd.UnknownNeoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell LungChina